“…Antibody positivity was associated with lower or undetectable circulating infliximab levels [21,24,26,27,30,32,[34][35][36][37][39][40][41], and a lower likelihood of disease control or remission [21,24,27,28,[35][36][37][38]42,43,46,52]. However, in a prospective study of patients with UC, undetectable infliximab concentrations were associated with less favorable clinical outcomes irrespective of antibody status [41], suggesting that antibody formation may not be the sole mechanism underlying the loss of efficacy.…”